Skip to main content
DNTH logo

Dianthus Therapeutics, Inc. (DNTH) Stock: Price, Forecast & Analyst Target

Dianthus Therapeutics, Inc. (DNTH) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $84.83 (+1.01%), as of the Nov 19, 2026 trading session; market cap $4.78B.

Educational signal · not a buy or sell recommendation · How to read this

$84.83 +$0.85 (+1.01%) Market Cap $4.78B

Dianthus Therapeutics, Inc. · DNTH · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune disease, with lead candidates in active development. The investment case depends on whether candidates can progress through clinical trials to approval and market adoption before the company's cash reserve diminishes.

Price as of Nov 19, 2026

Key Statistics

27 of 100

MoonshotScore v2 · Dianthus Therapeutics (DNTH)

Weak
Business Quality Thin (25)
Financial Safety Fortress (95)
Valuation Full (46)
Growth Durability Fading (29)
Momentum Surging (83)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but weak quality, weak growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • quarterly revenue $1M (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z 84.55 · Piotroski F 2

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DNTH (57 recorded, newest six shown)
RecordedScoreBand
26Weak
27Weak
27Weak
27Weak
27Weak
27Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$84.83
Change on the day+1.01%
52-week range$35.84–$117.88
Market capitalisation$4.78B—
Price / earnings (trailing)102.15
Shares traded on the day815.5K
Beta (volatility vs the S&P 500)0.08

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $33, high $116, latest $85. $116 $33 high $116 Oct 17, 2025 Nov 19, 2026 · $85 $36Oct 17, 2025$35Oct 31, 2025$41Nov 14, 2025$44Nov 28, 2025$42Dec 12, 2025$42Dec 26, 2025$38Jan 9, 2026$52Jan 23, 2026$51Feb 6, 2026$50Feb 20, 2026$65Mar 6, 2026$78Mar 20, 2026$86Apr 2, 2026$93Apr 17, 2026$87May 1, 2026$86May 15, 2026$93May 29, 2026$82Jun 12, 2026$95Jun 26, 2026$98Jul 10, 2026$104Jul 24, 2026$109Aug 7, 2026$111Aug 21, 2026$108Sep 4, 2026$97Sep 18, 2026$88Oct 2, 2026$72Oct 16, 2026$82Oct 30, 2026$92Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Dianthus Therapeutics (DNTH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Strong
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Dianthus Therapeutics (DNTH), and what does it report?

Short answer · as of

Dianthus does not yet have an approved product or significant revenue.

The company's reporting shows the classic clinical-stage biotech profile: minimal revenue from a licensing agreement, and operating losses driven entirely by research and development spending. The lead clinical candidate, claseprubart, is a monoclonal antibody engineered to target the active form of the complement protein with extended half-life and high selectivity, addressing complement-mediated inflammation in severe autoimmune conditions.

A second candidate targets plasmacytoid dendritic cells to suppress interferon production and suppress B cell function. Both are designed for conditions where few alternatives exist, which typically supports higher prices if approved.

2 · Latest results

What do the latest results show for Dianthus Therapeutics (DNTH)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1M.

The most recent quarter showed the highest cash burn rate the company has recorded. Research and development spending climbed sharply while revenue remained minimal and unstable, driven by the small licensing agreement with no growth visible in the near term. This acceleration reflects the company's movement deeper into clinical development, which is expected to become even more capital-intensive as trials expand.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1M-$47M-$0.81 (diluted)
Q2 FY2026$761,000-$50M-$0.90 (diluted)
Q1 FY2026$463,000-$41M-$0.85 (diluted)
Q4 FY2025$284,000$98M$2.59 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Dianthus Therapeutics (DNTH)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The company's major strength is the absolute scale of its cash reserve relative to the quarterly burn rate, which covers the projected timeline through the expected approval decision. Debt is nearly nonexistent, leaving cash as the only material liability. The central risk is the clinical and commercial success of the lead candidates; a failure in trials or poor market uptake would eliminate substantially all shareholder value. A secondary risk is that the burn rate will accelerate further or that the timeline to approval will extend, eroding the margin of safety that the current reserve provides.

Data-derived red flags

  • Negative return on equity (-3.9%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Rich valuation — a P/E of 102.15 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Dianthus Therapeutics (DNTH)?

Short answer · as of

Current published price targets run low $122.00 · high $158.00 · consensus $136.50 · median $133.00 against a quoted price of $84.83 (as of Nov 19, 2026).

Watch for clinical trial progression updates on leading candidates. The path to profitability requires approval and market adoption of the lead programs. Management's ability to preserve cash and extend runway through the approval decision is critical; any substantial deviation from the projected burn rate should trigger reassessment.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Dianthus Therapeutics compare with its peers?

Short answer

Dianthus Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Dianthus differs from stable pharmaceutical companies because it has no approved products and minimal revenue. It resembles other clinical-stage immunology companies in that its value is entirely contingent on clinical success. The focus on severe autoimmune indications narrows the addressable market compared to companies pursuing broader conditions, but the unmet medical need typically supports higher prices upon approval.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Named competitor$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.37 Nov 18, 2026$4.53B84 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$44.89 Nov 18, 2026$3.30B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.76 Nov 18, 2026$4.83B67 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.74 Nov 18, 2026$6.49B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.86 Nov 18, 2026$5.27B66 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.62 Nov 18, 2026$3.42B66 5-pillar Nov 18, 2026
Dianthus Therapeutics (DNTH) — this page$84.83$4.78B27

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$122.00 – $158.00
Consensus target
$136.50
Median target
$133.00

Consensus record · Captured .

Measured against a quoted price of $84.83 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
105
Identified insiders
7
Purchases
0
Sales
47
Other transactions
58

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DNTH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DNTH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Dianthus Therapeutics (DNTH)?

Read these with our analysis →

DNTH Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

What complement blockade program is Dianthus advancing?

The lead program blocks the active form of the complement protein, designed to suppress complement-driven inflammation in severe autoimmune conditions. A bifunctional fusion protein works through a distinct mechanism, suppressing interferon production and B cell activity. Both address indications with substantial unmet need; the company's rising research spending reflects the development intensity required, and analyst estimates for future revenue reflect expectations of clinical success.

How long can the company operate with its current cash and burn rate?

The company's cash reserve, when divided by the current quarterly operating cash consumption, extends the runway to a date well into the projected conclusion of clinical trials. If trials take longer or burn accelerates, this timeline shortens.

Why have insiders been selling shares?

Form filings show significant insider selling in recent periods from company leadership, with no offsetting purchases. Form data records only the transaction, not the reason, but such sales often reflect vesting taxation rather than loss of confidence. Analyst coverage remains uniformly positive despite this selling pattern, providing context to interpret the activity.

What do analysts expect for future revenue?

Analyst consensus projects minimal revenue in the near term, reflecting the expectation that the lead candidates remain in trials. Revenue estimates then expand significantly in the out years, conditional on regulatory approval and market uptake. The wide range between high and low estimates reflects the inherent uncertainty of clinical-stage biotech.

What is the DNTH stock price today?

The last price recorded for Dianthus Therapeutics, Inc. (DNTH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DNTH price target?

The analyst consensus price target for Dianthus Therapeutics, Inc. (DNTH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Cash, investments and debt; Employees
  • 1. What is Dianthus Therapeutics (DNTH), and what does it report?: Quarterly income statement (USD thousands); Business description; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Dianthus Therapeutics (DNTH)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Dianthus Therapeutics (DNTH)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Trailing twelve-month ratio set
  • 4. What should you watch next at Dianthus Therapeutics (DNTH)?: Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does Dianthus Therapeutics compare with its peers?: Sector / industry (provider taxonomy); Revenue by segment; Analyst revenue and earnings estimates (average)
  • FAQ: What complement blockade program is Dianthus advancing?: Business description; Annual revenue and net result (USD millions); Analyst revenue and earnings estimates (average)
  • FAQ: How long can the company operate with its current cash and burn rate?: Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Operating cash flow by quarter (USD millions)
  • FAQ: Why have insiders been selling shares?: Insider transactions, last 180 days; Named officers; Analyst actions, most recent per firm
  • FAQ: What do analysts expect for future revenue?: Analyst revenue and earnings estimates (average); Analyst actions, most recent per firm; Next earnings report
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.